Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2

Journal of Virology

Volumn 81, Issue 3, 2007, Pages 1444-1450

  Kim, Jae Ouk ^a   Chakrabarti, Bimal K ^a   Guha Niyogi, Anuradha ^a   Louder, Mark K ^a   Mascola, John R ^a   Ganesh, Lakshmanan ^a   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT; PHOSPHOLIPASE A2; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CELL LINE; HIV INFECTIONS; HIV-1; HUMANS; PHOSPHOLIPASES A; RECEPTORS, CXCR4; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 33846542383     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01790-06     Document Type: Article

References (28)

1. Aasa-Chapman, M. M., S. Holuigue, K. Aubin, M. Wong, N. A. Jones, D. Cornforth, P. Pellegrino, P. Newton, I. Williams, P. Borrow, and A. McKnight. 2005. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J. Virol. 79:2823-2830.
2. Aoki, K., C. Barker, X. Danthinne, M. J. Imperiale, and G. J. Nabel. 1999. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol. Med. 5:224-231.
3. 2-paradigm. Chem. Rev. 101:2613-2654.
4. 2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J. Biol. Chem. 275:3179-3191.
5. Brugger, B., B. Glass, P. Haberkant, I. Leibrecht, F. T. Wieland, and H. G. Krausslich. 2006. The HIV lipidome: a raft with an unusual composition. Proc. Natl. Acad. Sci. USA 103:2641-2646.
6. 2, a new class of HIV inhibitors that block virus entry into host cells. J. Clin. Investig. 104:611-618.
7. Gronroos, J. O., V. J. Laine, M. J. Janssen, M. R. Egmond, and T. J. Nevalainen. 2001. Bactericidal properties of group IIA and group V phospholipases A2. J. Immunol. 166:4029-4034.
8. 2 induced prominent release of arachidonic acid from human myeloid leukemia cells. J. Biol. Chem. 274:34203-34211.
9. 2 probed by the variants H48Q, H48N and H48K. Protein Eng. 12:497-503.
10. Kim, J. H., P. Pitisuttithum, C. Kamboonruang, T. Chuenchitra, J. Mascola, S. S. Frankel, M. S. DeSouza, V. Polonis, R. McLinden, A. Sambor, A. E. Brown, B. Phonrat, K. Rungruengthanakit, A. M. Duliege, M. L. Robb, J. McNeil, and D. L. Birx. 2003. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res. Hum. Retrovir. 19:807-816.
11. 2. J. Biol. Chem. 277:5849-5857.
12. 2 to Escherichia coli infection. Infect. Immun. 68:87-92.
13. Mascola, J. R., M. K. Louder, C. Winter, R. Prabhakara, S. C. DeRosa, D. C. Douek, B. J. Hill, D. Gabuzda, and M. Roederer. 2002. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 76:4810-4821.
14. 2. J. Biol. Chem. 280:23203-23214.
15. 2 prevents adenoviral infection in mammalian cells. Biochem. J. 393:97-106.
16. 2-α. J. Biol. Chem. 279:25024-25038.
17. 2s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem. 274:31435-31444.
18. 2s. Adv. Immunol. 77:163-194.
19. 2. Acta Crystallogr. D 55:443-447.
20. 2. J. Biol. Chem. 277:48535-48549.
21. Stoiber, H., M. Pruenster, C. G. Ammann, and M. P. Dierich. 2005. Complement-opsonized HIV: the free rider on its way to infection. Mol. Immunol. 42:153-160.
22. Sullivan, B. L., E. J. Knopoff, M. Saifuddin, D. M. Takefman, M. N. Saarloos, B. E. Sha, and G. T. Spear. 1996. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J. Immunol. 157:1791-1798.
23. 2. Biochem. Biophys. Res. Commun. 279:223-228.
24. 2. Rev. Physiol. Biochem. Pharmacol. 91:91-203.
25. Verity, E. E., L. A. Williams, D. N. Haddad, V. Choy, C. O'Loughlin, C. Chatfleld, N. K. Saksena, A. Cunningham, F. Gelder, and D. A. McPhee. 2006. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS 20:505-515.
26. 2. J. Clin. Investig. 97:250-257.
27. Wilson, J. A., M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664-1666.
28. Yang, Z.-Y., Y. Huang, L. Ganesh, K. Leung, W.-P. Kong, O. Schwartz, K. Subbarao, and G. J. Nabel. 2004. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78:5642-5650.